Today we are very pleased to announce alignment with the U.S. FDA on an Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry, accelerating estimated time to potential approval by approx. 3 yrs. Learn more:

We’re pleased to report updated data from our Ph 1/2 study in #Fabry Disease showing sustained benefit, improvements in kidney function and a favorable safety profile. Data will be shared at #WORLDSymposia on Feb. 6 at 9:30am PDT.

Happy Holidays from all of us at Sangamo! Dedication and passion fuel our mission to bring hope and innovation to those who need it most. Warm wishes for a joyful holiday season and a new year filled with health, happiness, and exciting possibilities!

Today we announce another important capsid delivery license agreement with @AstellasUS to deliver genomic medicines for neurological diseases. Learn more here:

ICYMI @pfizer unveiled detailed Ph3 AFFINE trial results at #ASH2024 for the treatment of adults with Hem A. These findings highlight the tolerability of giroctocogene fitelparvovec and its superior bleed protection compared to FVIII prophylaxis.

We’re excited for @pfizer #ASH2024 oral presentation today, showcasing data from Ph.3 AFFINE trial of giroctocogene fitelparvovec, a gene therapy that we co-developed with and licensed to PFE for the treatment of adults w/moderately severe to severe Hem A.

Join David Ojala at the Gene Therapy for CNS Summit for a presentation on our capsid delivery & epigenetic regulation technologies. He will share how SGMO is developing & characterizing an innovative BBB penetrant capsid designed to potentially revolutionize delivery to the CNS.

Today we are pleased to announce clearance from the FDA on our IND application for ST-503, an investigational epigenetic regulator for the treatment of chronic pain.

Our CEO, Sandy Macrae, is attending the Jefferies London Healthcare Conference this week, where he will connect with industry leaders and spotlight advancements in our pipeline.

Today we announce 3Q financial results and key biz updates, incl. alignment with FDA on an Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry, accelerating est. time to potential approval by approx. 3yrs

Our Q3 financial results will be announced on Tuesday, November 12, 2024, with a conference call at 4:30 PM ET. Details on how to join our conference call and webcast:

ICYMI: Last week at #Prion2024 Victoria Chou presented compelling data on Sangamo’s ZFR demonstrating reduction of the prion protein in animal models. To view the presentation,

Join Victoria Chou, Scientist at Sangamo, at #Prion2024 conference for a presentation on how our #ZincFinger Repressors could potentially treat Prion Disease:

We are delighted to announce our latest paper, showcasing advancements in our ZF platform - @biorxivpreprint. This study demonstrates that multiplexed ZFR's could potentially offer a safer alternative for knocking out immunosuppressive factors within TME.

September is #PainAwarenessMonth, a time to acknowledge the fact that millions of ppl live with chronic pain. SGMO is dedicated to advancing potential medicines that could transform the lives of patients with severe chronic pain. Together, we raise awareness.

We are pleased to announce another significant milestone with the publication of a new manuscript in bioRxiv, highlighting our promising genomic medicine approach intended to reduce excessive pain in patients with chronic neuropathic pain.

Join CEO Sandy Macrae, MRCP PhD for a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, Sept. 9th at 8:30 a.m. EDT. For the latest information, visit our website:

Join CEO Sandy Macrae, MRCP PhD for a fireside chat at the Wells Fargo Healthcare Conference on Friday, Sept. 6 at 12:00 p.m. EDT. For the latest information, visit our website:

We announce important Q2 financial results and key business updates incl. a🌍epigenetic regulation and capsid delivery license agreement w/@Genentech, reporting of @Pfizer’s + topline results from Ph3 AFFINE trial, and updates on other key biz developments

Today we are excited to announce a global epigenetic regulation and capsid delivery license agreement with @genentech to develop novel genomic medicines for neurodegenerative diseases. Learn more here: